Treating chronic kidney disease using clay minerals

January 15, 2014

Miss M. spends around 15 hours a week in hospital. Her renal functions are limited, and her kidneys are no longer able to filter toxins from her blood. She is a dialysis patient, forced to rely on this artificial blood purification treatment that, although essential, greatly impairs her quality of life. She has to make three trips a week to the dialysis clinic and going away for longer than a few days is almost out of the question. And Miss M. is no exception: In Germany alone, over six million people suffer from some form of chronic renal disease. Around 70,000 depend on dialysis and they are joined by some 15,000 new dialysis patients every year. Poor diet and an aging population are contributing to the dramatic rise in chronic renal disease worldwide, with high blood pressure and diabetes the most significant risk factors related to renal failure.

When suffering from renal failure, the body is unable to filter out phosphates in sufficient quantities, and the resulting excess is then absorbed into the blood. This causes a build-up of calcium-phosphate deposits in the blood vessels, which can over an extended period lead to arteriosclerotic heart disease and premature death. Compared to people with healthy kidneys, those with compromised renal function are at least ten times more likely to suffer a heart attack or stroke. To counteract this increased risk, people suffering from chronic renal insufficiency are required to take phosphate binders with meals. In the stomach and intestines, these medications bind to phosphates from food so that they can be excreted undigested instead of being absorbed into the blood. The problem is that existing medications, such as calcium and aluminum salts, cause serious side-effects including constipation, hypercalcemia (an elevated level of calcium in the blood), and neurologic disorders.

Gentle alternatives to pharmaceutical treatments

But hope is in sight for sufferers of chronic renal disease. Scientists from the Fraunhofer Institute for Cell Therapy and Immunology IZI in Rostock teamed up with FIM Biotech GmbH to develop an effective therapeutic agent that patients can tolerate well. Formed by marine deposits of volcanic ash 60 billion years ago, clay minerals found in the Friedland area of north-east Germany provide the basis for the new agent. The clay first has to be processed before being refined using a special technical process.

In a series of laboratory trials and cell culture experiments, the cooperation partners were able to prove the high phosphate-binding capacity and tolerance rate of the clay minerals. "The phosphate binder obtained from pure mineralogical raw materials is just as effective as traditional pharmaceutical binders. It can lower renal patients' elevated phosphate levels. Our tests using animal models show that, unlike standard medications, our binder causes only mild side-effects," says Prof. Dr. Steffen Mitzner, head of the Working Group on Extracorporeal Immunomodulation in Rostock and Professor of Nephrology at the city's university. The scientists believe that their refined natural raw material could also be used in the treatment of inflammatory bowel disease. Another animal model trial is currently underway to determine the scope of using clay minerals to help heal artificially induced bowel inflammation.

The Fraunhofer scientists and FIM Biotech GmbH have filed a patent application for their agent and refining technique. The animal trials are scheduled for completion by the end of 2013, and the scientists expect to be able to start passing on the benefits of the new agent to the first patients when clinical trials begin in early 2014.
-end-


Fraunhofer-Gesellschaft

Related Dialysis Articles from Brightsurf:

Immediate dialysis no better than wait-until-necessary approach, researchers find
In the largest international study of its kind, researchers at the University of Alberta and Toronto's St.

Predictors of 5-year mortality in young dialysis patients
The analysis published in NDT [1] evaluated for the first time the association of a large number of demographic, HD treatment and laboratory variables with mortality in patients on chronic hemodialysis treatment since childhood.

COVID-19 mortality alarmingly high in dialysis patients
Analysis of a Spanish experience shows that COVID-19 is frequent in hemodialysis patients, who appear to be at risk for worse outcome.

Survival following switch from urgent in-center hemodialysis to home dialysis
Few patients who start urgent and unplanned dialysis in clinical centers switch to home dialysis.

Is ownership of dialysis facilities associated with access to kidney transplants?
An analysis that included data for nearly 1.5 million patients with end-stage kidney disease looked at whether ownership of dialysis facilities was associated with patients' access to kidney transplants.

At-home dialysis improves quality of life
The rate of people starting voluntary at-home peritoneal dialysis rose from 15% to 34% over 10 years at Kaiser Permanente in Northern California, providing a convenient and safe way to manage advanced-stage kidney disease compared with center-based hemodialysis, according to research published today in JAMA Internal Medicine.

Hydration sensor could improve dialysis
Researchers from MIT and Massachusetts General Hospital have now developed a portable sensor that can accurately measure patients' hydration levels using a technique known as nuclear magnetic resonance (NMR) relaxometry.

Uncovering possible role of polyphosphate in dialysis-related amyloidosis
Researchers from Osaka University found that the low concentrations of the naturally occurring biopolymer, polyphosphate (polyP), induces amyloid formation from β2 microglobulin under both acidic and neutral conditions but by different mechanisms.

Study compares dialysis reimbursement around the globe
Dialysis reimbursement policies in most countries are focused on conventional in-center hemodialysis, although home hemodialysis and peritoneal dialysis might contribute to quality of life and cost savings.

Elderly patients on dialysis have a high risk of dementia
Older kidney disease patients who are sick enough to require the blood-filtering treatment known as dialysis are at high risk of dementia, including Alzheimer's disease, according to a study led by scientists at Johns Hopkins Bloomberg School of Public Health.

Read More: Dialysis News and Dialysis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.